Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 1

Conditions

Liver Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Acrocephalosyndactylia 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × derazantinib × Clear all
NCT04604132 2024-04-04

FIDES-03

Basilea Pharmaceutica

Phase 1/2 Terminated
47 enrolled 22 charts
Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

NCT03230318 2023-12-19

FIDES-01

Basilea Pharmaceutica

Phase 2 Completed
148 enrolled 15 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT04045613 2023-10-13

FIDES-02

Basilea Pharmaceutica

Phase 1/2 Completed
95 enrolled 25 charts
Genitourinary

Acrocephalosyndactylia, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01752920 2023-06-05

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Basilea Pharmaceutica

Phase 1/2 Completed
119 enrolled 15 charts
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡